Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026)
Ardelyx (ARDX) posted Non-Current Deffered Revenue of $13.7 million for Q1 2026, little changed on a QoQ basis from $13.7 million in Q4 2025, and up 64.06% year-over-year from $8.4 million in Q1 2025.
Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Ardelyx's Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 64.06% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (up 64.06% YoY) and the FY2025 annual result came in at $13.7 million, up 89.42% from the prior year.
- Non-Current Deffered Revenue was $13.7 million for Q1 2026 at Ardelyx, roughly flat from $13.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $13.7 million in Q3 2025 and bottomed at $7.2 million in Q4 2024.
- A 5-year average of $10.7 million and a median of $10.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 321.48% — and 2025, when it plunged 31.01%.
- Ardelyx's Non-Current Deffered Revenue stood at $9.0 million in 2022, then retreated by 4.22% to $8.6 million in 2023, then fell by 16.34% to $7.2 million in 2024, then surged by 89.42% to $13.7 million in 2025, then changed by 0.0% to $13.7 million in 2026.
- Business Quant data shows ARDX's Non-Current Deffered Revenue at $13.7 million in Q1 2026, $13.7 million in Q4 2025, and $13.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 13.70 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 12.77 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Dec 31, 2023 | 8.64 Mn |
| Sep 30, 2023 | 10.29 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 11.50 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 8.56 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 8.56 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 2.95 Mn |